Survival benefit seen for patients with ALS drug CNM-Au8: New data

Foralumab nasal spray joins pathway to HEALEY platform trial

A Phase 2 clinical trial to investigate Tiziana Life Sciences’ intranasal foralumab for the treatment of amyotrophic lateral sclerosis (ALS) has been accepted into the Healey ALS MyMatch program at Massachusetts General Hospital. The program, located at the Sean M. Healey & AMG Center for ALS, is a…